ViVac Pharma receives NIS 100,000 award for its work on programmable RNA immunotherapies targeting solid tumors. | Read More in JPost.com – Business & Innovation | The Jerusalem Post
Recent Posts
The Jerusalem Post
Are newsrooms burying Iranian efforts to influence midterms? – opinion
October 20, 2026- October 20, 2026
Iran prolongs talks in stalemate to punish Trump ahead of US midterms, officials say
October 20, 2026Eisenkot extends lead over Netanyahu in new poll, but neither bloc reaches majority
October 20, 2026
YnetNews
IDF will ‘allow democratic elections to take place without external interference,’ says IDF chief
October 20, 2026‘Bombing will resume sooner or later’: Iran prepares for US-Israeli attacks amid Hormuz tensions
October 20, 2026
IDF gives detained Chabad students a choice: enlist or face prisonOctober 20, 2026Report: UK to deploy fighter jets to defend Saudi Arabia from Houthi attacks
October 20, 2026
Arutz Sheva
Herzog in Hungary: ‘Alliance of freedom-loving nations critical to confronting Iran’October 20, 2026
High alert: The Chief of Staff’s pre-election messageOctober 20, 2026
French riots: Messi memorabilia lootedOctober 20, 2026
Special search effort for man missing near JerusalemOctober 20, 2026
JTA
- Israeli, Lebanese delegations meet at CENTCOM’s Tampa headquarters, IDF sources tell ‘Post’October 20, 2026
- Hebrew University start-up wins Asper Prize for approach to cancer treatmentOctober 20, 2026
- Hebrew University start-up wins Asper Prize for approach to cancer treatmentOctober 20, 2026
- Hebrew University start-up wins Asper Prize for approach to cancer treatmentOctober 20, 2026
Tesla approaches Q3 earnings amid Roadster buzz and expansion
October 20, 2026